STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 209.8

Change

-3.95 (-1.85)%

Market Cap

USD 0.72B

Volume

176.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-1.79 (-4.06%)

USD 55.57B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-29.10 (-5.59%)

USD 13.81B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-20.31 (-5.44%)

USD 12.91B
WRD:PA HSBC MSCI World UCITS ETF

-1.64 (-4.84%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-6.61 (-2.62%)

USD 9.42B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-25.15 (-5.72%)

USD 8.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

-17.61 (-5.24%)

USD 7.98B
HHH:PA HSBC S&P 500 UCITS ETF

-2.94 (-5.60%)

USD 7.67B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.24 (-3.40%)

USD 6.16B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

-6.00 (-7.15%)

USD 5.54B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.14% 56% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.14% 55% F 52% F
Trailing 12 Months  
Capital Gain -2.12% 16% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.12% 15% F 40% F
Trailing 5 Years  
Capital Gain 41.57% 30% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.57% 29% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 9.38% 56% F 63% D
Dividend Return 9.38% 53% F 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.87% 74% C 92% A
Risk Adjusted Return 119.23% 92% A 98% N/A
Market Capitalization 0.72B 72% C 74% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike